{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["51(10)"],"submitter":["Blair WS"],"pubmed_abstract":["More than 10(6) compounds were evaluated in a human immunodeficiency virus type 1 (HIV-1) high-throughput antiviral screen, resulting in the identification of a novel HIV-1 inhibitor (UK-201844). UK-201844 exhibited antiviral activity against HIV-1 NL4-3 in MT-2 and PM1 cells, with 50% effective concentrations of 1.3 and 2.7 microM, respectively, but did not exhibit measurable antiviral activity against the closely related HIV-1 IIIB laboratory strain. UK-201844 specifically inhibited the production of infectious virions packaged with an HIV-1 envelope (Env), but not HIV virions packaged with a heterologous Env (i.e., the vesicular stomatitis virus glycoprotein), suggesting that the compound targets HIV-1 Env late in infection. Subsequent antiviral assays using HIV-1 NL4-3/IIIB chimeric vi"],"journal":["Antimicrobial agents and chemotherapy"],"pagination":["3554-61"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC2043256"],"repository":["biostudies-literature"],"pubmed_title":["Identification and characterization of UK-201844, a novel inhibitor that interferes with human immunodeficiency virus type 1 gp160 processing."],"pmcid":["PMC2043256"],"pubmed_authors":["Patick AK","Cao J","Blair WS","Malfait AM","Butler SL","Wu H","Graham J","Chu A","Jimenez J","Isaacson J","Tortorella M","Peng Q","Jackson L"],"additional_accession":[]},"is_claimable":false,"name":"Identification and characterization of UK-201844, a novel inhibitor that interferes with human immunodeficiency virus type 1 gp160 processing.","description":"More than 10(6) compounds were evaluated in a human immunodeficiency virus type 1 (HIV-1) high-throughput antiviral screen, resulting in the identification of a novel HIV-1 inhibitor (UK-201844). UK-201844 exhibited antiviral activity against HIV-1 NL4-3 in MT-2 and PM1 cells, with 50% effective concentrations of 1.3 and 2.7 microM, respectively, but did not exhibit measurable antiviral activity against the closely related HIV-1 IIIB laboratory strain. UK-201844 specifically inhibited the production of infectious virions packaged with an HIV-1 envelope (Env), but not HIV virions packaged with a heterologous Env (i.e., the vesicular stomatitis virus glycoprotein), suggesting that the compound targets HIV-1 Env late in infection. Subsequent antiviral assays using HIV-1 NL4-3/IIIB chimeric vi","dates":{"release":"2007-01-01T00:00:00Z","publication":"2007 Oct","modification":"2025-06-01T01:12:08.711Z","creation":"2019-03-27T02:21:48Z"},"accession":"S-EPMC2043256","cross_references":{"pubmed":["17646410"],"doi":["10.1128/aac.00643-07","10.1128/AAC.00643-07"]}}